Factory Supply Bortezomib powder CAS: 179324-69-7 CAS NO.179324-69-7
- FOB Price: USD: 10.00-10.00 /Gram Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Available Specifications:
99%(500-1000)Gram
- Product Details
Keywords
- Bortezomib
- 179324-69-7
- Bortezomib powder
Quick Details
- ProName: Factory Supply Bortezomib powder CAS: ...
- CasNo: 179324-69-7
- Molecular Formula: C19H25BN4O4
- Appearance: white powder
- Application: anti-cancer
- DeliveryTime: in 7 days
- PackAge: 10G/bag
- Port: Shanghai/Beijing/Tianjin
- ProductionCapacity: 10 Metric Ton/Year
- Purity: 99%
- Storage: Room temperature
- Transportation: Regular transportation
- LimitNum: 1 Gram
- Related Substances: 0.1%
- Residue on Ignition: 0.1%
- Heavy Metal: 10ppm
- Valid Period: 3 years
Superiority
Why is SINOWAY:
1) Specialized in pharmaceutical and healthcare industrial for 34 years.
2) ISO 9001:2015 & SGS audited supplier .
3) Accept various payment terms : T.T 30-60 days.
4) We have warehouse in USA with quickly shipment .
5) We can do different terms of FOB ,CIF/CIP ,DDP ...
Our Advantange of Bortezomib powder CAS: 179324-69-7:
Best Quality and Competive price
Details
the information of Bortezomib powder CAS: 179324-69-7:
Product name |
Bortezomib |
CAS No. |
179324-69-7 |
Molecular Formula |
C19H25BN4O4 |
Molecular Weight |
384.24 |
Quality Standard |
99% up, Medicine Grade |
Appearance |
White powder |
The COA of Bortezomib powder CAS: 179324-69-7
The use of Bortezomib powder CAS: 179324-69-7:
Bortezomib is a new targeted drug for myeloma. The discovery of this drug has attracted wide attention in the medical field, and its mechanism of action won the Nobel Prize in Chemistry in 2004. In 2006, bortezomib was awarded the Highest honor in the pharmaceutical industry -- The International Galen Prize (PrixGalien).Before bortezomib, multiple myeloma was a nightmare for patients with the disease.
Bortezomib, as a breakthrough drug for myeloma, has the following advantages:
1.It only takes about 1 month to take effect.
2. The curative effect is remarkable, the remission rate can reach more than 80Chemicalbook%, and the complete remission rate can reach 30%~40%.Bortezomib in combination with lenalidomide and dexamethasone (BRD) extended median survival by 11 months compared with lenalidomide in combination with dexamethasone (RD), with median survival of 75 months in the BRD group.
3. High safety, can be applied to patients with renal insufficiency or even renal failure, the efficacy is equivalent to that of patients with normal renal function, and can reverse renal function;
4. Bortezomib based induction therapy can significantly increase the number and speed of stem cell collection.